There are six main types of sickle cell anemia, and the type you have dramatically affects how sick you get, how often you end up in the hospital, and what treatment you need. The most common and severe form is HbSS disease, where you inherit two copies of the sickle hemoglobin gene. From there, severity ranges down through HbSC disease, HbS beta-zero thalassemia, HbS beta-plus thalassemia, and the rarer variants like HbSD and HbSE.
This distinction matters more than most people realize. A patient with HbSS disease might have a baseline hemoglobin of 6–8 g/dL and experience multiple pain crises per year, while someone with HbSC disease might walk around with a hemoglobin of 10–12 g/dL and go years between serious complications. If you’ve been diagnosed with sickle cell disease—or carry the trait—knowing which type you’re dealing with is the first step toward getting the right care.
Quick Overview: What Makes Red Blood Cells “Sickle”?
Sickle cell disease (SCD) is caused by a point mutation in the hemoglobin-beta gene on chromosome 11. Normal red blood cells contain hemoglobin A (HbA), which keeps them flexible and disc-shaped. When the gene is mutated, it produces hemoglobin S (HbS), which polymerizes under low-oxygen conditions, deforming red blood cells into rigid, crescent-shaped “sickles.”
These sickled cells get stuck in small blood vessels, causing the hallmark vaso-occlusive pain crises, organ damage, and chronic anemia. In the United States, about 100,000 people live with SCD, and roughly 1 in 365 African-American newborns is affected. The disease also occurs frequently in people of Mediterranean, Indian, Middle Eastern, and Latin American descent.
The 6 Different Types of Sickle Cell Anemia, Explained
1. HbSS Disease (Sickle Cell Anemia)
This is the “classic” form and the one most people mean when they say sickle cell anemia. The person inherits an HbS gene from both parents. Nearly all hemoglobin produced is HbS, which means aggressive sickling, severe hemolytic anemia (baseline hemoglobin often 6–8 g/dL), and frequent pain crises. HbSS accounts for approximately 65% of all SCD cases in the U.S.
Patients with HbSS have the highest risk of stroke (11% by age 20 without screening), acute chest syndrome, splenic sequestration in childhood, and early organ damage. Median life expectancy has improved to the mid-40s to 50s with modern care, but it still falls well short of the general population.
2. HbSC Disease
The second most common type, making up about 25% of SCD cases. Here, the person inherits one HbS gene and one gene for hemoglobin C (HbC). Because HbC doesn’t polymerize as aggressively as HbS, the disease is generally milder. Hemoglobin levels tend to run 10–12 g/dL.
Don’t let “milder” fool you, though. HbSC carries a notably higher risk of proliferative retinopathy and avascular necrosis of the hip compared to HbSS. It’s also associated with increased risk of complications during pregnancy. These patients still need regular hematology follow-up.
3. HbS Beta-Zero (β⁰) Thalassemia
This type results from inheriting one HbS gene and one beta-thalassemia gene that produces zero beta-globin. Clinically, it behaves almost identically to HbSS disease—severe anemia, frequent crises, high complication rates. Hemoglobin electrophoresis shows no HbA at all, which is the key lab finding that distinguishes it from the beta-plus variant.
4. HbS Beta-Plus (β⁺) Thalassemia
Here, the beta-thalassemia gene still produces some beta-globin, so the patient makes a small amount of normal HbA (typically 5–25% on electrophoresis). This residual HbA acts as a buffer against sickling, resulting in milder symptoms and higher baseline hemoglobin. Many patients have a relatively benign course, but they still can experience pain crises and organ damage over time.
5. HbSD Disease
A rare variant where one HbS gene pairs with hemoglobin D-Punjab. Severity is variable but can mimic HbSS in some cases. It’s more commonly seen in people of Indian and Northwestern European descent.
6. HbSE Disease
Hemoglobin E is common in Southeast Asian populations. When inherited alongside HbS, the result is usually a mild to moderate disease. However, the clinical picture can vary, and some patients do develop significant complications.
Comparison Table: Types of Sickle Cell Anemia at a Glance
| Type | Genotype | Typical Hemoglobin (g/dL) | Severity | Frequency (U.S.) |
|---|---|---|---|---|
| HbSS | Two HbS genes | 6–8 | Severe | ~65% of SCD cases |
| HbSC | HbS + HbC | 10–12 | Mild to moderate | ~25% |
| HbS β⁰-thalassemia | HbS + β⁰-thal | 7–9 | Severe (similar to HbSS) | ~5% |
| HbS β⁺-thalassemia | HbS + β⁺-thal | 9–12 | Mild to moderate | ~3% |
| HbSD | HbS + HbD | Variable | Variable (can be severe) | Rare |
| HbSE | HbS + HbE | 9–11 | Mild to moderate | Rare |
How Is the Type Diagnosed?
In the U.S., all 50 states include sickle cell disease in their newborn screening panel. The initial screen uses a blood test (typically isoelectric focusing or HPLC) to detect abnormal hemoglobins. If the screen is positive, confirmatory testing with hemoglobin electrophoresis identifies the exact hemoglobin pattern—this is what tells you whether you’re dealing with HbSS, HbSC, HbS beta-thal, or another variant.
A complete blood count (CBC) and reticulocyte count provide supporting information about the degree of anemia and how hard the bone marrow is working to compensate. Genetic testing can be done if the electrophoresis results are ambiguous.
Treatment Differences by Type
Not all types are treated the same. Hydroxyurea, the first-line disease-modifying therapy, is most strongly recommended for HbSS and HbS β⁰-thalassemia. It works by boosting fetal hemoglobin (HbF) production, which interferes with HbS polymerization. Studies show it reduces pain crises by about 50% and lowers mortality.
Newer therapies like voxelotor (Oxbryta), crizanlizumab (Adakveo), and L-glutamine (Endari) are approved for SCD broadly, though most clinical trial data comes from HbSS patients. Gene therapy (Casgevy and Lyfgenia, FDA-approved in December 2023) represents a potential cure for severe forms, though access remains limited.
For milder types like HbSC and HbS β⁺-thalassemia, management often focuses on monitoring for specific complications—especially retinopathy in HbSC—and treating pain crises when they occur.
When to See a Doctor
- Severe pain crisis not responding to home medications within 1–2 hours
- Fever above 101.3°F (38.5°C)—this is a medical emergency in SCD due to infection risk from functional asplenia
- Sudden vision changes, especially in HbSC disease
- Chest pain, shortness of breath, or cough—could signal acute chest syndrome
- Sudden weakness, speech difficulty, or severe headache—possible stroke
- Priapism lasting more than 2 hours
- Rapid enlargement of the spleen in children (parents should learn to palpate the spleen)
Frequently Asked Questions
Which type of sickle cell anemia is the most severe?
HbSS disease and HbS beta-zero thalassemia are the most severe. Both produce virtually no normal hemoglobin A, leading to aggressive red blood cell sickling, severe chronic anemia, and the highest rates of complications like stroke, acute chest syndrome, and organ damage.
Can you have sickle cell disease and not know it?
Yes, particularly with milder types like HbSC or HbS β⁺-thalassemia. Some people aren’t diagnosed until adulthood when they have a complication or routine blood work shows abnormal hemoglobin. If you were born before universal newborn screening (implemented in all U.S. states by 2006), you may not have been tested.
Is sickle cell trait the same as having sickle cell disease?
No. Sickle cell trait (HbAS) means you carry one normal gene and one HbS gene. You produce enough normal HbA (typically 55–60%) to prevent sickling under normal conditions. Trait carriers are generally asymptomatic, though extreme conditions like high altitude, severe dehydration, or intense exertion can rarely trigger complications.
Does the type of sickle cell disease affect life expectancy?
Significantly. HbSS patients have a median life expectancy in the mid-40s to early 50s in the U.S., while those with HbSC disease typically live into their 60s. These numbers continue to improve with modern therapies, especially hydroxyurea and now gene therapy for severe forms.
Can two parents with sickle cell trait have a child with HbSC disease?
No. HbSC disease requires one parent to carry the HbS gene and the other to carry the HbC gene. Two HbAS (sickle cell trait) parents have a 25% chance of having a child with HbSS disease, a 50% chance of trait, and a 25% chance of completely normal hemoglobin.
